Showing 2 posts of 2 posts found.
A muscular drug developed by Novartis (NYSE: NVS), in partnership with MorphoSys (ETR: MOR), failed to meet its primary endpoint …
Care Quality Commission appoints Emily Miles as Chief Executive
National survey aims to improve glaucoma care across the UK
Phase 3 trials support expanded use of Dysport for migraine prevention
Roche secures CE Mark for automated latent tuberculosis blood test
ReproNovo Phase 2 fertility study doses first participant